Mariam Swidan: Hemolytic Anemia – Disease Overview
Mariam Swidan, Biomedical Science Graduate, Clinical Laboratory Professional, shared a post on LinkedIn:
“Hemolytic Anemia – Disease Overview
Definition
Hemolytic anemia is a condition characterized by premature destruction of red blood cells (RBCs), leading to a decreased RBC lifespan (less than 120 days) and insufficient compensation by the bone marrow.
Pathophysiology
- RBC destruction exceeds production
- Bone marrow responds – increased reticulocytes
- Hemoglobin breakdown – increased bilirubin
- Can occur intravascularly or extravascularly (spleen)
Classification
1. Intrinsic (RBC defect)
Usually hereditary
- Membrane defects (e.g., spherocytosis)
- Enzyme deficiencies (e.g., G6PD deficiency)
- Hemoglobinopathies (e.g., sickle cell disease, thalassemia)
2. Extrinsic (external factors)
Usually acquired
- Autoimmune hemolytic anemia
- Infections (e.g., malaria)
- Microangiopathic (DIC, TTP, HUS)
- Drugs/toxins
Clinical features
- Fatigue, pallor
- Jaundice (increased bilirubin)
- Dark urine (hemoglobinuria)
- Splenomegaly (especially extravascular)
Laboratory findings
Key pattern:
- Hb decreased
- Reticulocytes increased
- LDH increased
- Indirect bilirubin increased
- Haptoglobin decreased
Blood smear (depends on cause):
- Spherocytes
- Schistocytes
- Bite cells
Types of hemolysis
Intravascular
- RBC destruction in circulation
- Hemoglobinemia and hemoglobinuria
Extravascular
- RBC destruction in spleen/liver
- Increased splenomegaly, less hemoglobinuria
Management (depends on cause)
- Treat underlying condition
- Folic acid supplementation
- Immunosuppressants (if autoimmune)
- Splenectomy (selected cases)
- Blood transfusion if severe
The body tries to compensate for hemolysis by increasing RBC production – that’s why reticulocyte count is one of the most important markers in diagnosis.”
Stay updated with Hemostasis Today.
-
Aug 14, 2026, 06:26Delivering Gene Therapy in Hemophilia – ISTH
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials